

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

Lenti-iCas9-neo

RRID:Addgene_85400

Type: Plasmid

Proper Citation

RRID:Addgene_85400

Plasmid Information

URL: <http://www.addgene.org/85400>

Proper Citation: RRID:Addgene_85400

Insert Name: Flag-iCas9-P2A-GFP

Organism: Other

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:27458201](#)

Vector Backbone Description: Backbone Size:10000; Vector Backbone:pInducer-20; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: Lenti-iCas9-neo

Record Creation Time: 20220422T222549+0000

Record Last Update: 20260815T082123+0000

Ratings and Alerts

No rating or validation information has been found for Lenti-iCas9-neo.

No alerts have been found for Lenti-iCas9-neo.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li W, et al. (2026) A shear stress-responsive pathway in monocytes drives cardiopulmonary bypass-induced inflammation via spectrin/RAF1/store-operated calcium entry. *Cell reports*, 45(2), 116903.

Zanella E, et al. (2026) Damage-induced i-loops generate eccDNA from repetitive elements. *Molecular cell*, 86(10), 1856.

Kudo S, et al. (2025) Collaborative orchestration of BH3-only proteins governs Bak/Bax-dependent hepatocyte apoptosis under antiapoptotic protein-deficiency in mice. *Cell death and differentiation*, 32(6), 1153.

Zirman A, et al. (2025) Pooled CRISPR screens identifies key regulators of bovine stem cell expansion for cultured meat. *Communications biology*, 8(1), 1313.

Qiao J, et al. (2025) Immune metabolic changes identify causal candidate genes and enable diagnostic frameworks in MAFLD. *Scientific reports*, 15(1), 31751.

Zheng S, et al. (2025) High CDC20 levels increase sensitivity of cancer cells to MPS1 inhibitors. *EMBO reports*, 26(4), 1036.

Young AA, et al. (2025) PACT suppresses PKR activation through dsRNA binding and dimerization, and is a therapeutic target for triple-negative breast cancer. *RNA (New York, N.Y.)*, 31(11), 1599.

Wang J, et al. (2024) ATM and 53BP1 regulate alternative end joining-mediated V(D)J recombination. *Science advances*, 10(31), eadn4682.

Tinajero-Rodríguez JM, et al. (2024) ICAM1 (CD54) Contributes to the Metastatic Capacity of Gastric Cancer Stem Cells. *International journal of molecular sciences*, 25(16).

Wang J, et al. (2024) DNA-PKcs suppresses illegitimate chromosome rearrangements. *Nucleic acids research*, 52(9), 5048.

Yu VZ, et al. (2024) ?Np63-restricted viral mimicry response impedes cancer cell viability and remodels tumor microenvironment in esophageal squamous cell carcinoma. *Cancer letters*, 595, 216999.

Malla S, et al. (2024) The scaffolding function of LSD1 controls DNA methylation in mouse ESCs. *Nature communications*, 15(1), 7758.

Zhou F, et al. (2023) A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia. *Cancer discovery*, 13(2), 332.

Papalazarou V, et al. (2023) Phenotypic profiling of solute carriers characterizes serine transport in cancer. *Nature metabolism*, 5(12), 2148.

Luo Y, et al. (2023) mRNA interactions with disordered regions control protein activity. *bioRxiv : the preprint server for biology*.

Davis-Anderson K, et al. (2023) CRISPR/Cas9 Directed Reprogramming of iPSC for Accelerated Motor Neuron Differentiation Leads to Dysregulation of Neuronal Fate Patterning and Function. *International journal of molecular sciences*, 24(22).

Cai W, et al. (2022) A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma. *Cancer research*, 82(14), 2625.

Malla S, et al. (2022) ZFP207 sustains pluripotency by coordinating OCT4 stability, alternative splicing and RNA export. *EMBO reports*, 23(3), e53191.

Fagundes RR, et al. (2022) HIF1 α -Dependent Induction of TFRC by a Combination of Intestinal Inflammation and Systemic Iron Deficiency in Inflammatory Bowel Disease. *Frontiers in physiology*, 13, 889091.

Park SB, et al. (2022) A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells. *Molecular therapy. Nucleic acids*, 28, 656.